Matthew T. Huggett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Matthew T. Huggett has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Bharat Paranandi
Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
5 shared publications - Wafaa Ahmed
Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
3 shared publications - Ben Maher
Department of Interventional Radiology, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2 shared publications - Cyrus Piraka
Division of Gastroenterology and Hepatology, Henry Ford Health System, K7, 2799 W. Grand Boulevard, Detroit, MI 48202, USA
2 shared publications - Diana Jomaa
Chief Medical Resident, Department of Internal Medicine, Henry Ford Health, Detroit, Michigan, USA
2 shared publications Duyen Dang
2 shared publications
Latest Publications
- 19 June 2026
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (e1) , e156-e167
Techniques and application of EUS guided procedures in the pancreas and liver
Endoscopic ultrasound (EUS) has evolved from a diagnostic imaging modality into a therapeutic platform for hepatopancreatobiliary disease, allowing high-resolution assessment and targeted intervention during the same session. In hepatology, EUS-guided liver biopsy offers real-time vascular avoidance, bilobar sampling and high diagnostic adequacy, with a favourable safety profile and reduced post-procedural recovery compared with percutaneous approaches. EUS-guided portal pressure gradient measurement enables direct portal and hepatic venous manometry and may identify pre-sinusoidal portal hypertension that can be underestimated by hepatic venous pressure gradient assessment. EUS-guided vascular therapy, particularly combined coil embolisation and cyanoacrylate injection, permits Doppler-guided targeting of gastric variceal inflow vessels and is associated with high obliteration rates and reduced rebleeding compared with conventional glue injection in selected patients. In pancreatic disease, EUS-guided pancreatic duct drainage provides a minimally invasive salvage option when standard endoscopic retrograde pancreatography fails, using rendezvous or transmural techniques to restore ductal drainage, although adverse events and technical complexity remain important limitations. EUS-guided ablation, most commonly radiofrequency ablation or ethanol-based therapy, is increasingly used for selected pancreatic neuroendocrine tumours, cystic neoplasms and unresectable malignancy, offering symptom control or lesion regression in patients unsuitable for surgery. This review summarises established and emerging EUS-guided interventions in the liver and pancreas, focusing on procedural techniques, clinical outcomes, safety considerations and practical relevance for advanced hepato-pancreato-biliary (HPB) endoscopy services.
- 19 June 2026
- Published by BMJ in Frontline Gastroenterology
- Vol. 17 (e1) , e156-e167
Techniques and application of EUS guided procedures in the pancreas and liver
Endoscopic ultrasound (EUS) has evolved from a diagnostic imaging modality into a therapeutic platform for hepatopancreatobiliary disease, allowing high-resolution assessment and targeted intervention during the same session. In hepatology, EUS-guided liver biopsy offers real-time vascular avoidance, bilobar sampling and high diagnostic adequacy, with a favourable safety profile and reduced post-procedural recovery compared with percutaneous approaches. EUS-guided portal pressure gradient measurement enables direct portal and hepatic venous manometry and may identify pre-sinusoidal portal hypertension that can be underestimated by hepatic venous pressure gradient assessment. EUS-guided vascular therapy, particularly combined coil embolisation and cyanoacrylate injection, permits Doppler-guided targeting of gastric variceal inflow vessels and is associated with high obliteration rates and reduced rebleeding compared with conventional glue injection in selected patients. In pancreatic disease, EUS-guided pancreatic duct drainage provides a minimally invasive salvage option when standard endoscopic retrograde pancreatography fails, using rendezvous or transmural techniques to restore ductal drainage, although adverse events and technical complexity remain important limitations. EUS-guided ablation, most commonly radiofrequency ablation or ethanol-based therapy, is increasingly used for selected pancreatic neuroendocrine tumours, cystic neoplasms and unresectable malignancy, offering symptom control or lesion regression in patients unsuitable for surgery. This review summarises established and emerging EUS-guided interventions in the liver and pancreas, focusing on procedural techniques, clinical outcomes, safety considerations and practical relevance for advanced hepato-pancreato-biliary (HPB) endoscopy services.
- Open Access
- 10 March 2026
- Published by BMJ in Frontline Gastroenterology
British Society of Gastroenterology interim technical review and position on the use of lumen apposing metal stents during therapeutic endoscopic ultrasound following the urgent medical device recall of the AXIOS stent and electrocautery enhanced delivery system
Background On 20 December 2025, Boston Scientific initiated an urgent field safety notice and recall of selected Hot AXIOS lumen-apposing metal stent (LAMS) systems (6×8 mm, 8×8 mm and 20×10 mm) following reports of deployment and expansion failures at the time of delivery. These devices are widely used in the UK for therapeutic endoscopic ultrasound (T-EUS), including pancreatic fluid collection (PFC) drainage, EUS-guided gallbladder drainage (EUS-GBD), choledochoduodenostomy (EUS-CDD), gastrojejunostomy (EUS-GJ) and EUS-Directed transgastric endoscopic retrograde cholangio pancreatography (ERCP) (EDGE) procedures. The recall has immediate implications for urgent and complex interventions. Methods The British Society of Gastroenterology (BSG) Endoscopy Committee convened an expert working group comprising members of the committee and UK T-EUS leaders. Using evidence synthesised for the forthcoming BSG T-EUS Guidelines, the group developed consensus-based interim recommendations addressing alternative devices, technical strategies, salvage of stent maldeployment and governance measures. All recommendations achieved 100% agreement and were ratified by the BSG Endoscopy Committee. Results For PFC drainage and EUS-GBD, unaffected AXIOS sizes and alternative LAMS (eg, HOT SPAXUS, Z-EUS) remain viable options, with plastic stents or percutaneous approaches as adjuncts. The greatest impact is in malignant distal biliary obstruction, where withdrawal of 6×8 mm and 8×8 mm devices necessitates consideration of 10×10 mm LAMS in selected cases, alternative LAMS, tubular self-expanding metal stents, EUS-rendezvous, EUS-guided hepaticogastrostomy or antegrade stenting. For EUS-GJ and EDGE, the use of smaller LAMS or staged techniques is advised. Practical guidance for recognition and rescue of LAMS maldeployment is summarised, alongside recommendations for enhanced governance, regional collaboration and prospective data capture. Conclusion This interim BSG position statement provides pragmatic, consensus-driven guidance to maintain safe and effective T-EUS practice in the UK following the AXIOS recall. These recommendations support clinical decision-making during this period of device limitation and complement forthcoming national guidelines.
- 10 March 2026
- Published by BMJ in Frontline Gastroenterology
Open AccessBritish Society of Gastroenterology interim technical review and position on the use of lumen apposing metal stents during therapeutic endoscopic ultrasound following the urgent medical device recall of the AXIOS stent and electrocautery enhanced delivery system
Background On 20 December 2025, Boston Scientific initiated an urgent field safety notice and recall of selected Hot AXIOS lumen-apposing metal stent (LAMS) systems (6×8 mm, 8×8 mm and 20×10 mm) following reports of deployment and expansion failures at the time of delivery. These devices are widely used in the UK for therapeutic endoscopic ultrasound (T-EUS), including pancreatic fluid collection (PFC) drainage, EUS-guided gallbladder drainage (EUS-GBD), choledochoduodenostomy (EUS-CDD), gastrojejunostomy (EUS-GJ) and EUS-Directed transgastric endoscopic retrograde cholangio pancreatography (ERCP) (EDGE) procedures. The recall has immediate implications for urgent and complex interventions. Methods The British Society of Gastroenterology (BSG) Endoscopy Committee convened an expert working group comprising members of the committee and UK T-EUS leaders. Using evidence synthesised for the forthcoming BSG T-EUS Guidelines, the group developed consensus-based interim recommendations addressing alternative devices, technical strategies, salvage of stent maldeployment and governance measures. All recommendations achieved 100% agreement and were ratified by the BSG Endoscopy Committee. Results For PFC drainage and EUS-GBD, unaffected AXIOS sizes and alternative LAMS (eg, HOT SPAXUS, Z-EUS) remain viable options, with plastic stents or percutaneous approaches as adjuncts. The greatest impact is in malignant distal biliary obstruction, where withdrawal of 6×8 mm and 8×8 mm devices necessitates consideration of 10×10 mm LAMS in selected cases, alternative LAMS, tubular self-expanding metal stents, EUS-rendezvous, EUS-guided hepaticogastrostomy or antegrade stenting. For EUS-GJ and EDGE, the use of smaller LAMS or staged techniques is advised. Practical guidance for recognition and rescue of LAMS maldeployment is summarised, alongside recommendations for enhanced governance, regional collaboration and prospective data capture. Conclusion This interim BSG position statement provides pragmatic, consensus-driven guidance to maintain safe and effective T-EUS practice in the UK following the AXIOS recall. These recommendations support clinical decision-making during this period of device limitation and complement forthcoming national guidelines.
- 9 June 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 97 (6) , AB815-AB816
ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE OF INTRA-ABDOMINAL ABSCESS USING 15-MM VERSUS 10-MM LUMEN-APPOSING METAL STENTS: AN INTERNATIONAL, MULTICENTER, CASE-MATCHED STUDY
- 9 June 2023
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 97 (6) , AB815-AB816
ENDOSCOPIC ULTRASOUND-GUIDED DRAINAGE OF INTRA-ABDOMINAL ABSCESS USING 15-MM VERSUS 10-MM LUMEN-APPOSING METAL STENTS: AN INTERNATIONAL, MULTICENTER, CASE-MATCHED STUDY
- Open Access
- 10 October 2022
- Published by Springer Nature in Surgical Endoscopy
- Vol. 37 (3) , 1749-1755
Endoscopic ultrasound guided gastrojejunostomy in the treatment of gastric outlet obstruction: multi-centre experience from the United Kingdom
Background: Endoscopic ultrasound guided gastrojejunostomy (EUS-GJ) with lumen apposing metal stents has recently emerged as a viable option, as an alternative to surgical gastrojejunostomy and endoscopic enteral stenting, for managing gastric outlet obstruction (GOO). We aim to perform a retrospective analysis of the efficacy, safety and outcomes of EUS-GJ performed at three tertiary institutions in the United Kingdom. Methods: Consecutive patients who underwent EUS-GJ between August 2018 and March 2021 were identified from a prospectively maintained database. Data were obtained from interrogation of electronic health records. Results: Twenty five patients (15 males) with a median age of 63 years old (range 29–80) were included for analysis. 88% (22/25) of patients had GOO due to underlying malignant disease. All patients were deemed surgically inoperable or at high surgical risk. Both technical and clinical success were achieved in 92% (23/25) of patients. There was an improvement in the mean Gastric Outlet Obstruction Scoring System scores following a technically successful EUS-GJ (2.52 vs 0.68, p < 0.01). Adverse events occurred in 2/25 patients (8%), both due to stent maldeployment necessitating endoscopic closure of the gastric defect with clips. Long-term follow-up data were available for 21 of 23 patients and the re-intervention rate was 4.8% (1/21) over a median follow-up period of 162 (range 5–474) days. Conclusion: EUS-GJ in carefully selected patients is an effective and safe procedure when performed by experienced endoscopists.
- 10 October 2022
- Published by Springer Nature in Surgical Endoscopy
- Vol. 37 (3) , 1749-1755
Open AccessEndoscopic ultrasound guided gastrojejunostomy in the treatment of gastric outlet obstruction: multi-centre experience from the United Kingdom
Background: Endoscopic ultrasound guided gastrojejunostomy (EUS-GJ) with lumen apposing metal stents has recently emerged as a viable option, as an alternative to surgical gastrojejunostomy and endoscopic enteral stenting, for managing gastric outlet obstruction (GOO). We aim to perform a retrospective analysis of the efficacy, safety and outcomes of EUS-GJ performed at three tertiary institutions in the United Kingdom. Methods: Consecutive patients who underwent EUS-GJ between August 2018 and March 2021 were identified from a prospectively maintained database. Data were obtained from interrogation of electronic health records. Results: Twenty five patients (15 males) with a median age of 63 years old (range 29–80) were included for analysis. 88% (22/25) of patients had GOO due to underlying malignant disease. All patients were deemed surgically inoperable or at high surgical risk. Both technical and clinical success were achieved in 92% (23/25) of patients. There was an improvement in the mean Gastric Outlet Obstruction Scoring System scores following a technically successful EUS-GJ (2.52 vs 0.68, p < 0.01). Adverse events occurred in 2/25 patients (8%), both due to stent maldeployment necessitating endoscopic closure of the gastric defect with clips. Long-term follow-up data were available for 21 of 23 patients and the re-intervention rate was 4.8% (1/21) over a median follow-up period of 162 (range 5–474) days. Conclusion: EUS-GJ in carefully selected patients is an effective and safe procedure when performed by experienced endoscopists.
- Open Access
- 31 August 2022
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 26 (4) , 318-324
Initial United Kingdom experience of endoscopic ultrasound-directed transgastric endoscopic retrograde cholangiopancreatography
Puneet Chhabra, Wei On, Bharat Paranandi, Matthew T. Huggett, Naomi Robson, Mark Wright, Ben Maher, Nadeem Tehami. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.22-019
- 31 August 2022
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 26 (4) , 318-324
Open AccessInitial United Kingdom experience of endoscopic ultrasound-directed transgastric endoscopic retrograde cholangiopancreatography
Puneet Chhabra, Wei On, Bharat Paranandi, Matthew T. Huggett, Naomi Robson, Mark Wright, Ben Maher, Nadeem Tehami. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.22-019
P137 Intraductal fully covered self-expanding metal stents in biliary strictures: a UK multicentre experience
Introduction Fully covered intraductal self-expanding metal stents (IDSEMS) have been well described in the management of post-liver transplant anastomotic strictures (AS). They are increasingly used in a non-transplant (NT) setting. We conducted a multi-centre study across nine tertiary centres in the UK to analyse their use and efficacy Methods Consecutive patients who underwent Endoscopic Retrograde Cholangiopancreatography (ERCP) with insertion of IDSEMS were retrospectively analysed. Results 178 episodes (109 males, 61%) were identified. 162 (91%) underwent IDSEMS stent insertion for AS and 16 (9%) for a NT indication. Age at transplant was 54 years (range 12-74) and stent duration was 15 weeks (range three days-78 weeks). 131 (81%) had complete resolution of stricture at endoscopic re-evaluation. Stricture recurrence was observed in 13 (10%) cases. The most frequent indication for stenting in the NT setting was bile leak post partial hepatectomy (n=8, 50%). In the NT cohort, stent duration was 15 weeks (range 2- 41 weeks). 10 (83%) patients had complete resolution of biliary pathology on stent removal. At removal, there were 26 (14%) adverse events, five (3%) episodes of cholangitis and two (1%) of pancreatitis. In 13 (7%) cases the removal wires unravelled, 3 (2%) stents migrated, and three (2%) stents were embedded. All were removed endoscopically. Conclusions IDSEMS appear to be safe and highly efficacious in the management of post-liver transplant AS, with low rates of AS recurrence. IDSEMS can be effectively used in the non-transplant setting.
P137 Intraductal fully covered self-expanding metal stents in biliary strictures: a UK multicentre experience
Introduction Fully covered intraductal self-expanding metal stents (IDSEMS) have been well described in the management of post-liver transplant anastomotic strictures (AS). They are increasingly used in a non-transplant (NT) setting. We conducted a multi-centre study across nine tertiary centres in the UK to analyse their use and efficacy Methods Consecutive patients who underwent Endoscopic Retrograde Cholangiopancreatography (ERCP) with insertion of IDSEMS were retrospectively analysed. Results 178 episodes (109 males, 61%) were identified. 162 (91%) underwent IDSEMS stent insertion for AS and 16 (9%) for a NT indication. Age at transplant was 54 years (range 12-74) and stent duration was 15 weeks (range three days-78 weeks). 131 (81%) had complete resolution of stricture at endoscopic re-evaluation. Stricture recurrence was observed in 13 (10%) cases. The most frequent indication for stenting in the NT setting was bile leak post partial hepatectomy (n=8, 50%). In the NT cohort, stent duration was 15 weeks (range 2- 41 weeks). 10 (83%) patients had complete resolution of biliary pathology on stent removal. At removal, there were 26 (14%) adverse events, five (3%) episodes of cholangitis and two (1%) of pancreatitis. In 13 (7%) cases the removal wires unravelled, 3 (2%) stents migrated, and three (2%) stents were embedded. All were removed endoscopically. Conclusions IDSEMS appear to be safe and highly efficacious in the management of post-liver transplant AS, with low rates of AS recurrence. IDSEMS can be effectively used in the non-transplant setting.
- 1 February 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (4_suppl) , 272
Outcome and patterns of care in advanced biliary tract carcinoma (ABC): Experience from two tertiary institutions in the United Kingdom.
272 Background: The ABC-02 trial has defined the standard therapy for patients with advanced biliary tract cancer (ABC), however outcome in an unselected patient population in the UK has not been described. We report the outcome of a series of patients with ABC from two large UK cancer networks. Methods: We retrospectively reviewed all cases of ABC presenting to two UK cancer networks over a 9-year period. Patients with a diagnosis recorded under anatomical site (liver, gallbladder or biliary tree) or histological diagnosis (cholangiocarcinoma or adenocarcinoma, liver), were included. Any patients who had surgery with curative intent were excluded. Overall survival (OS) and factors influencing OS were assessed. For the analysis, chemotherapy regimens were considered as: (i) gemcitabine (G)-based vs. non-G-based, (ii) platinum (P)-based vs. non-P-based and (iii) fluoropyrimidine (F)-based vs. non-F-based. Results: 402 patients were available for analysis. The median OS was 6.2 months. On univariate analysis, age ≥ 70 years (p=0.047), advanced disease stage (p<0.001), gall bladder primary (p=0.033), poor performance status (p<0.001) and lack of chemotherapy (p<0.001) were associated with worse outcome. Survival was superior in the 36.4% of patients who received palliative chemotherapy (12.5 versus 4.3 months; p<0.001). In patients receiving chemotherapy, on multivariate analysis males had higher mortality than females (HR=1.71; p=0.006) and stage 4 disease had a higher mortality (HR=2.62; p=0.002) than stage 1-2 disease. Patients who did not receive F-based regimens (HR=5.12; p=0.022) or G-based regimens (HR=5.01; p=0.021) had a higher mortality, whereas the effect of P-containing regimens was of borderline significance (HR=2.23; p=0.086). Sites, age, and multi-agent regimens were not significant. Conclusions: This is the first retrospective series from the UK and one of the largest population-based studies in ABC and confirms the benefit of palliative chemotherapy in an unselected group of patients. F-based regimens appear to be as effective as G-based treatments.
- 1 February 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (4_suppl) , 272
Outcome and patterns of care in advanced biliary tract carcinoma (ABC): Experience from two tertiary institutions in the United Kingdom.
272 Background: The ABC-02 trial has defined the standard therapy for patients with advanced biliary tract cancer (ABC), however outcome in an unselected patient population in the UK has not been described. We report the outcome of a series of patients with ABC from two large UK cancer networks. Methods: We retrospectively reviewed all cases of ABC presenting to two UK cancer networks over a 9-year period. Patients with a diagnosis recorded under anatomical site (liver, gallbladder or biliary tree) or histological diagnosis (cholangiocarcinoma or adenocarcinoma, liver), were included. Any patients who had surgery with curative intent were excluded. Overall survival (OS) and factors influencing OS were assessed. For the analysis, chemotherapy regimens were considered as: (i) gemcitabine (G)-based vs. non-G-based, (ii) platinum (P)-based vs. non-P-based and (iii) fluoropyrimidine (F)-based vs. non-F-based. Results: 402 patients were available for analysis. The median OS was 6.2 months. On univariate analysis, age ≥ 70 years (p=0.047), advanced disease stage (p<0.001), gall bladder primary (p=0.033), poor performance status (p<0.001) and lack of chemotherapy (p<0.001) were associated with worse outcome. Survival was superior in the 36.4% of patients who received palliative chemotherapy (12.5 versus 4.3 months; p<0.001). In patients receiving chemotherapy, on multivariate analysis males had higher mortality than females (HR=1.71; p=0.006) and stage 4 disease had a higher mortality (HR=2.62; p=0.002) than stage 1-2 disease. Patients who did not receive F-based regimens (HR=5.12; p=0.022) or G-based regimens (HR=5.01; p=0.021) had a higher mortality, whereas the effect of P-containing regimens was of borderline significance (HR=2.23; p=0.086). Sites, age, and multi-agent regimens were not significant. Conclusions: This is the first retrospective series from the UK and one of the largest population-based studies in ABC and confirms the benefit of palliative chemotherapy in an unselected group of patients. F-based regimens appear to be as effective as G-based treatments.